|
Balance Sheet Cash Flow Statement 830 Winter St. Waltham, MA 02451-1477 MA Tel. 781-895-0600 Fax 781-895-0611 |
Type: Public
On the web:
http://www.immunogen.com
Employees:
210
Employee growth: 0.0%
ImmunoGen is TAPping into cancer research. The firm's product candidates are TAPs, or tumor-activated prodrugs, that combine cancer-killing drugs with monoclonal antibodies and attach only to tumor cells. On its own, ImmunoGen is developing two clinical-stage compounds: IMGN242, a TAP drug candidate to treat gastrointestinal cancers and some non-small-cell lung cancers; and IMGN901, which targets small-cell lung cancer and multiple myeloma. The firm has additional candidates in clinical trials through partnerships with Genentech and Sanofi-Aventis, and it has outlicensed its TAP technology to the likes of Biogen Idec and Centocor.
Key numbers for fiscal year ending June, 2009:
Sales: $28.0M
One year growth: (30.5%)
Net income: ($31.9)M
Officers:
Chairman: Stephen C. McCluski
President, CEO, and Director: Daniel M. (Dan) Junius
SVP and CFO: Gregory D. (Greg) Perry
Competitors:
Immunomedics
Medarex
Seattle Genetics
